Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
University of Kansas Medical Center
National Cancer Institute (NCI)
Mayo Clinic
Emory University
Northwestern University
OHSU Knight Cancer Institute
Mayo Clinic
M.D. Anderson Cancer Center
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
Alliance for Clinical Trials in Oncology
City of Hope Medical Center
Emory University
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National University Hospital, Singapore
Centre Hospitalier Universitaire de Besancon
Centre Hospitalier Universitaire de Besancon
City of Hope Medical Center
Icahn School of Medicine at Mount Sinai
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Sir Run Run Shaw Hospital
Technical University of Munich
OHSU Knight Cancer Institute
Karolinska University Hospital
University of California, San Diego
AIDS Malignancy Consortium